Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs: OPAL Broaden, a randomized, placebo-controlled, phase 3 trial

Author(s):
Mease, P.; Hall, S.; FitzGerald, O.; Heijde, D. van der; Merola, J.; Avila-Zapata, F.; Graham, D.; Wang, C.; Kanik, K.
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-06-30
Language
English
Is part of
Journal of The American Academy of Dermatology (2017), Vol. 76, no. 6, p. AB114-AB114
hdl
1887/114607